Developer docs
API playgroundTry for free, no card

Search company profiles

S2 Genomics

Full company profile

uuid0000ccd

Namestring
S2 Genomics
Legal namestring
S2 Genomics, Inc.
Websiteurl
s2genomics.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomic analyses. S2 Genomics was founded in 2016 and is headquartered in Livermore, CA.

Short descriptiontext

S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLivermore, United States
HQ citystring
Livermore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tissue dissociation instruments, single-cell genomics, automated sample preparation, cell counting instruments, FFPE nuclei processing
Industry1 code
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Laboratory Instruments for Single-Cell Genomics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Instruments and Consumables
TypeHardware Sales
Description

S2 Genomics generated revenue through the sale of Singulator tissue dissociation instruments along with associated consumables and reagents for single-cell sample preparation

finsmes.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

S2 Genomics develops and manufactures the Singulator platform, an automated tissue dissociation system that converts solid tissue samples (fresh, frozen, and FFPE) into sequencing-ready single-cell or nuclei suspensions for downstream single-cell genomics research. The company also offers complementary Coulter-principle cell counting instruments (Moxi line) and fluorescence phenotyping systems used as upstream quality control for sequencing workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 10x more viable cells recovered vs. gentleMACS in peer-reviewed glioblastoma study with 96% viability
Product overview1 text field

Precision Cell Systems (formerly S2 Genomics) offers an integrated portfolio of precision instruments for cell-based workflows serving single-cell genomics research. The product line centers on the Singulator platform (Singulator 100, 200, 200+) for automated tissue dissociation, which converts fresh, frozen, and FFPE tissues into sequencing-ready single cells or nuclei suspensions. Complementary instruments include the Moxi line (Moxi V, Moxi Z, Moxi GO II) for Coulter-principle cell counting and fluorescence analysis, providing upstream precision for downstream sequencers and cytometers. The Velocyt instrument rounds out the portfolio for cell analysis applications. These instruments address specific workflow bottlenecks including tissue dissociation, cell counting, and quality control steps that traditionally introduce variance in single-cell genomics.

Product and service7 records
1Singulator 100
CategoryTissue Dissociation Instruments
Description

Automated tissue dissociation instrument for processing fresh and frozen tissues into single-cell or nuclei suspensions for single-cell genomics; validated for 2 mg minimum input with enzyme-free protocols.

2Singulator 200
CategoryTissue Dissociation Instruments
Description

Enhanced automated tissue dissociation system with expanded tissue type support including FFPE processing capability, delivering software-locked reproducibility across sites for standardized single-cell sample preparation.

3Singulator 200+ System
CategoryTissue Dissociation Instruments
Description

Flagship automated tissue dissociation system featuring fully automated FFPE-to-nuclei processing without xylene. Processes tissue samples in 40–60 minutes with more than 1 million nuclei yield from a single 50 µm FFPE curl, eliminating toxic solvents and manual ethanol series through GREEN cartridge technology.

4Moxi V
CategoryCell Counting Instruments
Description

Volumetric Coulter-principle cell counter offering less than 2% CV precision with 8-second results. Features zero maintenance cassette-based design with volumetric debris exclusion and supports nuclei counting protocols.

5Moxi Z
CategoryCell Counting Instruments
Description

Enhanced Coulter-principle cell counter with expanded dynamic range for counting and sizing cells from 5–60 µm. Used for PBMC analysis, WBC counting, and proliferation assays with NIST-traceable precision.

6Moxi GO II
CategoryCell Counting and Fluorescence Instruments
Description

Combined Coulter-principle counting and two-color fluorescence cell counter/analyzer. Features 488nm laser with dual PMTs for viability, GFP, apoptosis, and immunophenotyping assays, with native 21 CFR Part 11 compliance for regulated environments. Results in under 10 seconds with FCS 3.1 export and FlowJo compatibility.

7Velocyt
CategoryCell Analysis Instruments
Description

Cell analysis instrument for fluorescence phenotyping and cell counting workflows within the company's single-cell analysis portfolio.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Precision Cell Systems
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-17
Description

S2 Genomics was acquired by Precision Cell Systems in September 2025 as part of a consolidation strategy. The acquisition combined S2 Genomics with ORFLO to create a company serving over 700 customers with more than 1,000 instruments.

prnewswire.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Miltenyi Biotec
TypeDirect peer
Description

Miltenyi Biotec's gentleMACS is the dominant automated tissue dissociation platform that the Singulator directly competes against and is benchmarked against (10x more viable cells recovered in a published glioblastoma study).

210x Genomics
TypeBroad incumbent
Description

10x Genomics is the leading single-cell and spatial genomics platform whose Chromium, Xenium, and Visium instruments are validated downstream of the Singulator; serves overlapping customers with a much broader portfolio spanning sequencing kits to instruments.

3NanoString Technologies
TypeDirect peer
Description

NanoString is a spatial transcriptomics platform mentioned as adjacent/competing in S2 Genomics' market context and overlaps in FFPE-based spatial workflows targeted by the Singulator 200+.

4Akoya Biosciences
TypeDirect peer
Description

Akoya is a spatial phenomics platform explicitly cited as a spatial genomics competitor in S2 Genomics' market context; both companies compete for spatial and single-cell research budgets from translational and immuno-oncology labs.

5Vizgen
TypeDirect peer
Description

Vizgen's MERSCOPE spatial transcriptomics platform is explicitly called out as a downstream integration and competing technology in S2 Genomics' market context, serving FFPE and fresh tissue spatial workflows.

6Parse Biosciences
TypeEmerging player
Description

Parse Biosciences offers single-cell sequencing solutions (Evercode) and is a validated downstream integration partner for Singulator-prepared samples, competing more broadly for single-cell research spend.

7Mission Bio
TypeEmerging player
Description

Mission Bio's Tapestri single-cell multi-omics platform is a validated Singulator downstream integration, serving overlapping oncology and translational research customers with a different downstream modality.

8Bio-Rad Laboratories
TypeBroad incumbent
Description

Bio-Rad is a broad life sciences instrument and consumables supplier (including ddPCR and cell sorting) that competes for similar cell-biology and genomics research budgets and serves many of the same core facilities.

9Beckman Coulter Life Sciences
TypeBroad incumbent
Description

Beckman Coulter (a Danaher company) provides flow cytometry, cell counting, and lab automation products that overlap with the Moxi line and compete for cell analysis workflow spend in research and bioprocessing.

10Becton Dickinson (BD)
TypeBroad incumbent
Description

BD Biosciences offers flow cytometry, cell sorting, and single-cell genomics sample prep instruments that overlap with both the dissociation and cell-counting workflows addressed by S2 Genomics' Singulator and Moxi platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration12 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

S2 Genomics

Laboratory Instruments for Single-Cell Genomicss2genomics.com

S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.

What S2 Genomics does

S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomic analyses. S2 Genomics was founded in 2016 and is headquartered in Livermore, CA.

S2 Genomics firmographics

Firmographics
Name
S2 Genomics
Legal name
S2 Genomics, Inc.
Website
https://s2genomics.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
1–10 employees
Short description
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.
Ownership category
akta.pro rank

S2 Genomics industry classification

Industry
Product category
Laboratory Instruments for Single-Cell Genomics
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Tissue dissociation instruments
  • Single-cell genomics
  • Automated sample preparation
  • Cell counting instruments
  • FFPE nuclei processing

Where S2 Genomics is headquartered

Location

Headquarters

HQ city
Livermore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

S2 Genomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Instruments and Consumables: S2 Genomics generated revenue through the sale of Singulator tissue dissociation instruments along with associated consumables and reagents for single-cell sample preparation

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

S2 Genomics product offering

Product offering

Core offering

S2 Genomics develops and manufactures the Singulator platform, an automated tissue dissociation system that converts solid tissue samples (fresh, frozen, and FFPE) into sequencing-ready single-cell or nuclei suspensions for downstream single-cell genomics research. The company also offers complementary Coulter-principle cell counting instruments (Moxi line) and fluorescence phenotyping systems used as upstream quality control for sequencing workflows.

Product overview

Precision Cell Systems (formerly S2 Genomics) offers an integrated portfolio of precision instruments for cell-based workflows serving single-cell genomics research. The product line centers on the Singulator platform (Singulator 100, 200, 200+) for automated tissue dissociation, which converts fresh, frozen, and FFPE tissues into sequencing-ready single cells or nuclei suspensions. Complementary instruments include the Moxi line (Moxi V, Moxi Z, Moxi GO II) for Coulter-principle cell counting and fluorescence analysis, providing upstream precision for downstream sequencers and cytometers. The Velocyt instrument rounds out the portfolio for cell analysis applications. These instruments address specific workflow bottlenecks including tissue dissociation, cell counting, and quality control steps that traditionally introduce variance in single-cell genomics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Singulator 100 Automated tissue dissociation instrument for processing fresh and frozen tissues into single-cell or nuclei suspensions for single-cell genomics; validated for 2 mg minimum input with enzyme-free protocols.
  • Singulator 200 Enhanced automated tissue dissociation system with expanded tissue type support including FFPE processing capability, delivering software-locked reproducibility across sites for standardized single-cell sample preparation.
  • Singulator 200+ System Flagship automated tissue dissociation system featuring fully automated FFPE-to-nuclei processing without xylene. Processes tissue samples in 40–60 minutes with more than 1 million nuclei yield from a single 50 µm FFPE curl, eliminating toxic solvents and manual ethanol series through GREEN cartridge technology.
  • Moxi V Volumetric Coulter-principle cell counter offering less than 2% CV precision with 8-second results. Features zero maintenance cassette-based design with volumetric debris exclusion and supports nuclei counting protocols.
  • Moxi Z Enhanced Coulter-principle cell counter with expanded dynamic range for counting and sizing cells from 5–60 µm. Used for PBMC analysis, WBC counting, and proliferation assays with NIST-traceable precision.
  • Moxi GO II Combined Coulter-principle counting and two-color fluorescence cell counter/analyzer. Features 488nm laser with dual PMTs for viability, GFP, apoptosis, and immunophenotyping assays, with native 21 CFR Part 11 compliance for regulated environments. Results in under 10 seconds with FCS 3.1 export and FlowJo compatibility.
  • Velocyt Cell analysis instrument for fluorescence phenotyping and cell counting workflows within the company's single-cell analysis portfolio.

Quantifiable outcome

  • 10x more viable cells recovered vs. gentleMACS in peer-reviewed glioblastoma study with 96% viability

Companies that use S2 Genomics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

S2 Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration12 records

Feature2 records

S2 Genomics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Precision Cell SystemsmajorStrategic or Co-development Partner · 17 September 2025S2 Genomics was acquired by Precision Cell Systems in September 2025 as part of a consolidation strategy. The acquisition combined S2 Genomics with ORFLO to create a company serving over 700 customers with more than 1,000 instruments.

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

S2 Genomics competitors and assessment

Company assessment

Direct peers

  • Miltenyi Biotec: Miltenyi Biotec's gentleMACS is the dominant automated tissue dissociation platform that the Singulator directly competes against and is benchmarked against (10x more viable cells recovered in a published glioblastoma study).
  • NanoString Technologies: NanoString is a spatial transcriptomics platform mentioned as adjacent/competing in S2 Genomics' market context and overlaps in FFPE-based spatial workflows targeted by the Singulator 200+.
  • Akoya Biosciences: Akoya is a spatial phenomics platform explicitly cited as a spatial genomics competitor in S2 Genomics' market context; both companies compete for spatial and single-cell research budgets from translational and immuno-oncology labs.
  • Vizgen: Vizgen's MERSCOPE spatial transcriptomics platform is explicitly called out as a downstream integration and competing technology in S2 Genomics' market context, serving FFPE and fresh tissue spatial workflows.

Broad incumbents

  • 10x Genomics: 10x Genomics is the leading single-cell and spatial genomics platform whose Chromium, Xenium, and Visium instruments are validated downstream of the Singulator; serves overlapping customers with a much broader portfolio spanning sequencing kits to instruments.
  • Bio-Rad Laboratories: Bio-Rad is a broad life sciences instrument and consumables supplier (including ddPCR and cell sorting) that competes for similar cell-biology and genomics research budgets and serves many of the same core facilities.
  • Beckman Coulter Life Sciences: Beckman Coulter (a Danaher company) provides flow cytometry, cell counting, and lab automation products that overlap with the Moxi line and compete for cell analysis workflow spend in research and bioprocessing.
  • Becton Dickinson (BD): BD Biosciences offers flow cytometry, cell sorting, and single-cell genomics sample prep instruments that overlap with both the dissociation and cell-counting workflows addressed by S2 Genomics' Singulator and Moxi platforms.

Emerging players

  • Parse Biosciences: Parse Biosciences offers single-cell sequencing solutions (Evercode) and is a validated downstream integration partner for Singulator-prepared samples, competing more broadly for single-cell research spend.
  • Mission Bio: Mission Bio's Tapestri single-cell multi-omics platform is a validated Singulator downstream integration, serving overlapping oncology and translational research customers with a different downstream modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

S2 Genomics social profiles

Digital presence

S2 Genomics compliance and trust

Trust signal

Compliance3 records

S2 Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

S2 Genomics leadership team

Management profile

Number of profiles

Profiles2 records

S2 Genomics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

S2 Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about S2 Genomics

What does S2 Genomics do?

S2 Genomics develops and manufactures the Singulator platform, an automated tissue dissociation system that converts solid tissue samples (fresh, frozen, and FFPE) into sequencing-ready single-cell or nuclei suspensions for downstream single-cell genomics research. The company also offers complementary Coulter-principle cell counting instruments (Moxi line) and fluorescence phenotyping systems used as upstream quality control for sequencing workflows.

Is S2 Genomics a public or private company?

S2 Genomics is a private company. It is classified as venture growth investor backed and is currently acquired.

When was S2 Genomics founded?

S2 Genomics was founded in 2016. It employs 1 to 10 people.

Where is S2 Genomics based?

S2 Genomics is headquartered in Livermore, United States, in the North America region.

How does S2 Genomics make money?

One revenue line is on record: instruments and Consumables.

Who are S2 Genomics's main competitors?

Direct peers on record are Miltenyi Biotec, NanoString Technologies, Akoya Biosciences and Vizgen. Broad incumbents are 10x Genomics, Bio-Rad Laboratories, Beckman Coulter Life Sciences and Becton Dickinson (BD). Emerging players are Parse Biosciences and Mission Bio.

Does S2 Genomics have an API?

No public API is recorded for S2 Genomics.

What industry is S2 Genomics in?

S2 Genomics's product category is Laboratory Instruments for Single-Cell Genomics. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSpatial Genomics and Transcriptomics Market is expected to Hit US$ 811.0 Million by 2033 | Major Companies - NanoString Technologies Inc, S2 Genomics Inc, Akoya Biosciences, ION path IncDataM Intelligence released a market research report projecting the Spatial Genomics and Transcriptomics Market will grow from US$ 328.5 million in 2025 to US$ 811.0 million by 2033, representing a compound annual growth rate of 9.35%. Key recent transactions in the sector include Complete Genomics entering a definitive acquisition agreement with Swiss Rockets, Bruker continuing post-acquisition integration of NanoString Technologies, and Vizgen securing a $100 million Series C financing round led by RA Capital Management for its MERSCOPE platform.openPR.comFFPE Tissue Samples For Genomics Study and Analysis Market to Surpass US$ 1.5 Billion by 2034, Driven by Rising Cancer Incidence and Genomic Advancements | Latest Report TMRTransparency Market Research published a market report projecting the global FFPE tissue samples market for genomics study and analysis to grow from US$891.1 million in 2023 to over US$1.5 billion by 2034, expanding at a compound annual growth rate of 5.1%. Market growth is driven by rising cancer incidence, increasing adoption of genomic technologies, and the growing importance of personalized medicine. Key developments include S2 Genomics launching the Singulator 200+ System in April 2024, while the market faces challenges including sample degradation, regulatory requirements, and high genomic analysis costs.PR NewswirePrecision Cell Systems Completes Two Acquisitions to Consolidate Best-in-Class Technologies Serving 700+ Customers for Cell AnalysisPrecision Cell Systems launched after acquiring S2 Genomics and ORFLO, consolidating cell analysis technologies. The company reports over 1,000 installed instruments, 700+ active customers, and a 35% operating expense reduction. It plans further acquisitions to build a comprehensive workflow platform.BioSpaceS2 Genomics Raises Series A Round Led by BroadOak Capital Partners and RCTS2 Genomics has raised $16 million in Series A funding led by BroadOak Capital Partners and Research Corporation Technologies to accelerate the commercial adoption of its Singulator platform. This investment supports the expansion of the company's customer base and the addition of new applications for its automated tissue dissociation technology used in neuroscience and oncology research.FinSMEsS2 Genomics Raises $16M in Series A FundingS2 Genomics, a Livermore-based manufacturer of single-cell genomics tools, raised $16 million in Series A funding led by BroadOak Capital Partners and Research Corporation Technologies. The company plans to utilize the capital to accelerate the commercial adoption of its Singulator platform, which automates tissue sample preparation for neuroscience and oncology research.Pulse 2.0S2 Genomics: Tissue Sample Preparation Company Raises Series AS2 Genomics has raised $16 million in Series A funding from BroadOak Capital Partners and Research Corporation Technologies to accelerate the commercial adoption of its Singulator tissue sample preparation platform. The funding aims to expand the customer base and add new applications for the automated single-cell genomics system, which is already used by academic and pharmaceutical organizations globally.BioSpaceS2 Genomics Announces Distribution Agreement with Bonsailab to Serve Iberian PeninsulaS2 Genomics announced a distribution agreement with Bonsailab to sell its Singulator 100 and 200 single-cell genomics systems in Spain and Portugal. The partnership aims to provide automated tissue dissociation solutions for single-cell applications in the Iberian Peninsula.BioSpaceS2 Genomics Announces New Distribution Partnership to Advance Single Cell Research for the Singulator™ 100 System with Proteigene in FranceS2 Genomics announced a distribution agreement with Proteigene to promote and sell its Singulator 100 System for single-cell genomics in France. The partnership aims to expand the product line through Proteigene's sales force and customer base, aligning with both companies' growth initiatives.BioSpaceS2 Genomics signs Eisenberg for Israel Distribution for the Singulator™ 100 System to Accelerate Single-Cell Genomics ResearchS2 Genomics announced a distribution agreement with Eisenberg to promote and sell its Singulator 100 system for single-cell genomics in Israel. The system automates tissue dissociation using disposable cartridges and proprietary reagents. Eisenberg's CEO said the partnership expands their single-cell product portfolio.